| Drug Name: | Pronethalol (51-02-5) |
|---|---|
| PubChem ID: | 60975 |
| SMILES: | CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O.Cl |
| InchiKey: | QONLGXRPRAIDGI-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 265.784 |
| LogP | : | 3.293 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 32.26 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Increased Beta-Blockade | CYP2D6 (P10635) | Increased beta-blockade [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|